[1] Soloviev D, Fini A, Chierichetti F, et al. PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging, 2008, 35(5): 942-949.  doi: 10.1007/s00259-007-0662-4
[2] Pike VW, Eakins MN, Allan RM, et al. Preparation of [1-11C] acetate—an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot, 1982, 33(7): 505-512.  doi: 10.1016/0020-708X(82)90003-5
[3] Luong A, Hannah VC, Brown MS, et al. Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. J Biol Chem, 2000, 275(34): 26458-26466.  doi: 10.1074/jbc.M004160200
[4] Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol, 2001, 28(2): 117-122.
[5] Yeh SH, Liu RS, Wu LC, et al. 11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commun, 1999, 20(2): 131-134.
[6] Dusing RW, Drisko JA, Grado GG, et al. Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies. Urol Clin North Am, 2011, 38(3): 343-357.  doi: 10.1016/j.ucl.2011.04.003
[7] Oyama N, Kim J, Jones LA, et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol, 2002, 29(8): 783-790.
[8] Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med, 2006, 36(1): 51-72.
[9] Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med, 2004, 34(4): 274-292.
[10] Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med, 2003, 44(4): 549-555.
[11] Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging, 2003, 30(4): 607-611.  doi: 10.1007/s00259-002-1104-y
[12] Mena E, Turkbey B, Mani H, et al. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med, 2012, 53(4): 538-545.
[13] Seppälä J, Seppänen M, Arponen E, et al. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol, 2009, 93(2): 234-240.
[14] Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of[11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging, 2002, 29(11): 1492-1495.  doi: 10.1007/s00259-002-0885-3
[15] Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med, 2003, 44(2): 213-221.
[16] Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and[N-methyl-11C]-choline. Q J Nucl Med Mol Imaging, 2009, 53(2): 144-156.
[17] Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med, 2008, 49(12): 1912-1921.  doi: 10.2967/jnumed.108.055087
[18] Cheung TT, Chan SC, Ho CL, et al. Can positron emission tomography with the dual tracers [11C]acetate and [18F] fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma. Liver Transpl, 2011, 17(10): 1218-1225.  doi: 10.1002/lt.22362
[19] Magini G, Farsad M, Frigerio M, et al. C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med, 2009, 34(10): 659-665.  doi: 10.1097/RLU.0b013e3181b53488
[20] Lhommel R, Annet L, Bol A, et al. PET scan with 11C-acetate for the imaging of liver masses: report of a false positive case. Eur J Nucl Med Mol Imaging, 2005, 32(5): 629.  doi: 10.1007/s00259-004-1698-3
[21] Yamamoto Y, Nishiyama Y, Kimura N, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol, 2008, 10(5): 281-287.
[22] Liu RS, Chang CP, Guo WY, et al. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med, 2010, 51(6): 883-891.
[23] Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med, 1995, 36(9): 1595-1601.
[24] Oyama N, Okazawa H, Kusukawa N, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging, 2009, 36(3): 422-427.  doi: 10.1007/s00259-008-0981-0
[25] Kotzerke J, Linné C, Meinhardt M, et al.[1-11C]Acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging, 2007, 34(6): 884-888.  doi: 10.1007/s00259-006-0362-5
[26] Ho CL, Chen S, Ho KM, et al. 11C-acetate PET/CT in multicentric angiomyolipoma of the kidney. Clin Nucl Med, 2011, 36(5): 407-408.
[27] Orevi M, Klein M, Mishani E, et al. 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med, 2012, 37(4): e67-72.
[28] Sun A, Sörensen J, Karlsson M, et al. 1-[11C]-acetate PET imaging in head and neck cancer—a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging, 2007, 34(5): 651-657.  doi: 10.1007/s00259-006-0298-9
[29] Sun A, Johansson S, Turesson I, et al. Imaging tumor perfusion and oxidative metabolism in patients with head-and-neck cancer using 1-[11C]-acetate PET during radiotherapy: preliminary results. Int J Radiat Oncol Biol Phys, 2012, 82(2): 554-560.  doi: 10.1016/j.ijrobp.2010.11.007
[30] Nomori H, Shibata H, Uno K, et al. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma. J Thorac Oncol, 2008, 3(12): 1427-1432.  doi: 10.1097/JTO.0b013e31818ddfdc
[31] Shibata H, Nomori H, Uno K, et al. 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med, 2009, 23(7): 609-616.
[32] Higashi K, Ueda Y, Matsunari I, et al. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET. Eur J Nucl Med Mol Imaging, 2004, 31(1): 13-21.  doi: 10.1007/s00259-003-1326-7
[33] Kaji M, Nomori H, Watanabe K, et al. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography of pulmonary adenocarcinoma. Ann Thorac Surg, 2007, 83(1): 312-314.  doi: 10.1016/j.athoracsur.2006.05.085
[34] Lee SM, Kim TS, Lee JW, et al. Incidental finding of an 11C-acetate PET-positive multiple myeloma. Ann Nucl Med, 2010, 24(1): 41-44.
[35] Sakurai H, Kaji M, Suemasu K. Thymoma of the middle mediastinum: 11C-acetate positron emission tomography imaging. Ann Thorac Surg, 2009, 87(4): 1271-1274.  doi: 10.1016/j.athoracsur.2008.07.109
[36] Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med, 1997, 38(8): 1305-1310.